Literature DB >> 12079862

Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients.

Francesco S Facchini1, Kami L Saylor.   

Abstract

Controversy surrounds the role of iron (Fe) in atherosclerosis (ASCVD), mainly due to the inaccuracy of assessing body Fe stores with serum ferritin and transferrin saturation. Quantitative phlebotomy was used to test whether or not (a) Fe stores are increased in individuals at high risk for ASCVD and (b) Fe depletion to near-deficiency (NID) levels is associated with reduction of risk factors for ASCVD. Thirty-one carbohydrate-intolerant subjects completed the study. Fe stores were within normal limits (1.5 +/- 0.1 g). At NID, a significant increase of HDL-cholesterol (p < 0.001) and reductions of blood pressure (p < 0.001), total and LDL-cholesterol (p < 0.001), triglyceride (p < 0.001), fibrinogen (p < 0.001) and glucose and insulin responses to oral glucose loading (p < 0.001) were noted, while homocysteine plasma concentration remained unchanged. These effects were largely reversed by a 6-month period of Fe repletion with reinstitution of Fe sufficiency. Thus, although individuals at high risk for ASCVD are not Fe-overloaded, they seem to benefit, metabolically and hemodynamically, from lowering of body Fe to levels commonly seen in premenopausal females.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079862     DOI: 10.1111/j.1749-6632.2002.tb04290.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

1.  Diabetes, cancer and iron.

Authors:  L Mascitelli; F Pezzetta; M R Goldstein
Journal:  Diabetologia       Date:  2010-06-23       Impact factor: 10.122

Review 2.  Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver.

Authors:  Elmar Aigner; Günter Weiss; Christian Datz
Journal:  World J Hepatol       Date:  2015-02-27

3.  The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor.

Authors:  Li Zhang; Louise Fairall; Benjamin T Goult; Anna C Calkin; Cynthia Hong; Christopher J Millard; Peter Tontonoz; John W R Schwabe
Journal:  Genes Dev       Date:  2011-06-15       Impact factor: 11.361

4.  The association of biomarkers of iron status with mortality in US adults.

Authors:  A Menke; P Muntner; J M Fernández-Real; E Guallar
Journal:  Nutr Metab Cardiovasc Dis       Date:  2011-02-16       Impact factor: 4.222

Review 5.  Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease.

Authors:  Qurat-ul-ain Jelani; Stuart D Katz
Journal:  Cardiol Rev       Date:  2010 Sep-Oct       Impact factor: 2.644

6.  The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention.

Authors:  Leo R Zacharski; Ralph G DePalma; Galina Shamayeva; Bruce K Chow
Journal:  Am J Public Health       Date:  2013-02-14       Impact factor: 9.308

7.  Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver.

Authors:  Paola Dongiovanni; Luca Valenti; Anna Ludovica Fracanzani; Stefano Gatti; Gaetano Cairo; Silvia Fargion
Journal:  Am J Pathol       Date:  2008-02-02       Impact factor: 4.307

Review 8.  Iron deficiency anemia in heart failure.

Authors:  Natasha P Arora; Jalal K Ghali
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

9.  Back to past leeches: repeated phlebotomies and cardiovascular risk.

Authors:  Melania Manco; Josè Manuel Fernandez-Real
Journal:  BMC Med       Date:  2012-05-30       Impact factor: 8.775

10.  Does long-term coffee intake reduce type 2 diabetes mellitus risk?

Authors:  Gustavo D Pimentel; Juliane Cs Zemdegs; Joyce A Theodoro; João F Mota
Journal:  Diabetol Metab Syndr       Date:  2009-09-16       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.